Research programme: stem cell modulators - Boston Biomedical

Drug Profile

Research programme: stem cell modulators - Boston Biomedical

Alternative Names: Cancer stem cell pathway inhibitor - Boston Biomedical; Cancer stemness kinase inhibitor - Boston Biomedical; Stem cell modulating cancer therapeutics - Boston Biomedical

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Biomedical
  • Class Antineoplastics
  • Mechanism of Action Phosphotransferase inhibitors; Signal transduction pathway inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top